Omnipod Lawsuit: 2026 Pod Recalls, Securities Class Action, and Injury Claims

Omnipod is a tubeless, wearable insulin pump made by Insulet Corporation. Each pod sticks to the skin and delivers insulin through a small cannula for up to three days. Omnipod 5 connects to a continuous glucose monitor for automated insulin delivery. It is used by people with diabetes who need insulin.

March 12, 2026 correction: internal tubing tear

Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod 5 pods distributed in the U.S. It said certain pods may have a small tear in the internal tubing, so insulin can leak inside the pod instead of being infused. Insulet reported 18 serious adverse events tied to high blood glucose, including hospitalization and DKA, and no deaths, and said the affected pods were about 1.5% of annual Omnipod 5 pod production.

May 26, 2026 correction: cannula tear

A separate, larger correction covered lots of Omnipod 5, Omnipod DASH, and Omnipod (Eros) pods in the U.S. and other markets. Some pods may have a small tear in the cannula just above the skin, so insulin leaks outside the pod. Users might notice wetness or an insulin smell, but Insulet warned the leak can be hard to detect.

Both corrections involve a recall-type action on a medical device. A recall alone does not prove anyone was harmed or that Insulet is legally liable.

Insulet said it has identified the causes of the manufacturing issues, updated its manufacturing processes and quality controls, and has enough supply to replace affected pods without disrupting shipments or new patient starts. Insulet's May 2026 announcement said the affected pods represent about 8.5% of its 2025 global pod production. For how a recall differs from a lawsuit, see our guide on recall vs. class action, and for lawsuits people can join now, see open lawsuits.

The securities class action

Hu v. Insulet Corporation, et al., No. 1:26-cv-13062-LTS, is a putative class action in the U.S. District Court for the District of Massachusetts. It alleges Insulet and certain executives made false and misleading statements about the quality and safety of Omnipod products, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The proposed class covers people who bought or acquired Insulet securities between February 21, 2025 and May 26, 2026. Insulet says it will defend the case and has not recorded a loss accrual. This case is for investors; it does not compensate patients.

Injury claims

As of September 2026, there was no multidistrict litigation or certified class for pod users, and no settlement. Attorneys are reviewing individual claims from people hospitalized after using affected pods. Whether those cases are filed and later consolidated will depend on how many serious injuries are documented.

Insulet also disclosed that its stock-related case is at an early stage and that it does not believe a loss is probable. The company separately won a trade secret judgment in 2025 against a competitor over Omnipod technology, a case unrelated to patient injuries.

An injury claim generally needs:

• An affected lot. Insulet publishes lot lists and a lot-check tool at omnipod.com. Keep your boxes or supplier records.
• A serious event tied to under-delivery: DKA, severe hyperglycemia needing emergency care, hospitalization, or death.
• A timeline showing the event happened while using a pod from an affected lot.

People who noticed a leak, swapped the pod, and had no medical harm usually do not have a damages claim, though they should still request free replacements. Users of other pump brands are not affected by these corrections.

DKA can have other triggers, such as illness, missed doses, or a pod falling off. The strongest injury claims link a specific pod from an affected lot to rising glucose readings and a documented DKA admission within the same period. Parents of children using Omnipod can bring claims on their behalf. If you were hospitalized and later received Insulet's correction notice, keep both records together, along with any replacement-pod confirmation from Insulet.

Users outside the United States may be covered by the May correction but would bring any claim under their own country's law.

No Omnipod injury case has settled or gone to trial, so there are no payout figures. In individual product cases, damages can include hospital and ICU costs, lost wages for patients or parents, and pain and suffering. A wrongful death case would add losses to the family.

By Insulet's own counts, 18 serious adverse events were reported at the March correction and 24 globally at the May correction, with no deaths reported in either announcement, which suggests the number of people with significant injuries may be limited relative to the millions of pods involved. In the securities case, any recovery would go to investors who lost money on the stock.

For the securities case, recoveries in cases like this usually depend on how many shares were bought during the class period and the price declines tied to the alleged disclosures. Investors typically do not need to do anything until a settlement or judgment, when notice is sent and claim forms become available.

Injury claims would be state-law product liability claims. Because Insulet describes both problems as manufacturing issues affecting specific lots, a manufacturing defect theory, that particular pods departed from their intended design, is the most direct path. Failure to warn and negligence claims may also be raised.

The securities case is different. It alleges violations of Section 10(b) of the Securities Exchange Act and SEC Rule 10b-5, which prohibit material misstatements in connection with buying or selling securities, and Section 20(a), which can make controlling officers liable. A lead plaintiff is typically appointed to run such a case.

A recall or correction is not proof of liability, but a company's own statement that specific lots had a manufacturing issue can be strong evidence in a manufacturing defect case if you can show you used one of those lots. The harder part is usually proving that the leak, rather than another cause, led to the DKA episode, which is why pump and CGM data matter.

Injury claims are governed by your state's statute of limitations, commonly two or three years from the injury. For a DKA hospitalization in 2025 or 2026, the clock generally started on the date of the event or when you learned it was tied to a defective pod. Claims involving minors often have longer deadlines, but rules vary by state.

For investors, the securities case sets its own deadlines through the court, including the lead plaintiff process.

Keep in mind that corrections announced in 2026 may involve pods used in 2025. If you had an unexplained DKA episode while using Omnipod pods in the past two years, check whether those lots were affected before assuming it was unrelated.

Investors in the securities case should watch for court notices about any settlement and claim deadlines; those are separate from any personal injury deadline. If you are unsure which deadline applies to you, a short review with an attorney can sort it out.

Insulet set up lot-check tools for each correction. For the March 12, 2026 action, it directed Omnipod 5 users to omnipod.com/check-pods. For the May 26, 2026 action, it pointed users to its Check Pod Lot page at omnipod.com/mdc/check-pod-lot, which lists every affected lot. Insulet Product Support is available at 1-800-641-2049.

Key facts from Insulet's announcements

Insulet said about 60% of the roughly 7 million pods in the May correction had already been used or had expired by the time of the announcement, which means many users will need supplier or pharmacy records to confirm which lots they had. Insulet also said the problems do not affect continuous glucose monitor readings.

Injury claim or securities claim?

Some people could be in both groups, for example a pod user who also owned Insulet stock during the class period. The two claims are handled separately.

1. Check your lot numbers using Insulet's lot-check tool and stop using affected pods, as Insulet instructs.
2. Request free replacements from Insulet if your pods are affected.
3. Keep affected pods and boxes rather than throwing them away, and write down lot numbers.
4. If you were hospitalized, request ER and hospital records and export your pump and CGM data.
5. Watch your glucose closely and follow your diabetes care team's instructions.

In a case review, expect questions about which Omnipod system you use, the lot numbers or supply dates for the pods in use at the time, what happened to your glucose, and what emergency or hospital care followed. Exporting your pump and CGM data soon after an event helps, because some apps and devices keep only limited history. If you do not have lot numbers, your pharmacy or durable medical equipment supplier may be able to tell you which lots they shipped.

Independent attorneys who handle medical device cases can review whether you have an injury claim. A free case review takes about two minutes. Related: the Ozempic lawsuit, the metformin lawsuit, and our guide on recalls versus class actions.